927 related articles for article (PubMed ID: 18343273)
21. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
Strutton DR; Farkouh RA; Earnshaw SR; Hwang S; Theidel U; Kontodimas S; Klok R; Papanicolaou S
J Infect; 2012 Jan; 64(1):54-67. PubMed ID: 22085813
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.
Ray GT; Pelton SI; Klugman KP; Strutton DR; Moore MR
Vaccine; 2009 Nov; 27(47):6483-94. PubMed ID: 19720366
[TBL] [Abstract][Full Text] [Related]
23. Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy.
Boccalini S; Azzari C; Resti M; Valleriani C; Cortimiglia M; Tiscione E; Bechini A; Bonanni P
Vaccine; 2011 Nov; 29(51):9521-8. PubMed ID: 22008820
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.
Giglio ND; Cane AD; Micone P; Gentile A
Vaccine; 2010 Mar; 28(11):2302-10. PubMed ID: 20064478
[TBL] [Abstract][Full Text] [Related]
25. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
[TBL] [Abstract][Full Text] [Related]
26. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
Mangtani P; Roberts JA; Hall AJ; Cutts FT
Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
[TBL] [Abstract][Full Text] [Related]
27. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
28. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).
Díez-Domingo J; Ridao-López M; Gutiérrez-Gimeno MV; Puig-Barberá J; Lluch-Rodrigo JA; Pastor-Villalba E
Vaccine; 2011 Dec; 29(52):9640-8. PubMed ID: 22027484
[TBL] [Abstract][Full Text] [Related]
29. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
30. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
Postma MJ; Heijnen ML; Beutels P; Jager JC
Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
[TBL] [Abstract][Full Text] [Related]
31. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
[TBL] [Abstract][Full Text] [Related]
32. Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical.
Newall AT; Reyes JF; McIntyre P; Menzies R; Beutels P; Wood JG
Vaccine; 2016 Jan; 34(3):320-7. PubMed ID: 26657187
[TBL] [Abstract][Full Text] [Related]
33. Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar).
Rozenbaum MH; Hoek AJ; Hak E; Postma MJ
Vaccine; 2010 Mar; 28(12):2367-9. PubMed ID: 20085833
[TBL] [Abstract][Full Text] [Related]
34. Economic evaluation of pneumococcal conjugate vaccination in Finland.
Salo H; Sintonen H; Nuorti JP; Linna M; Nohynek H; Verho J; Kilpi T
Scand J Infect Dis; 2005; 37(11-12):821-32. PubMed ID: 16308215
[TBL] [Abstract][Full Text] [Related]
35. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.
Kellner JD; Vanderkooi OG; MacDonald J; Church DL; Tyrrell GJ; Scheifele DW
Clin Infect Dis; 2009 Jul; 49(2):205-12. PubMed ID: 19508165
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.
Blank PR; Szucs TD
Vaccine; 2012 Jun; 30(28):4267-75. PubMed ID: 22521287
[TBL] [Abstract][Full Text] [Related]
37. Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(42):1148-51. PubMed ID: 18946462
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007.
Ardanuy C; Tubau F; Pallares R; Calatayud L; Domínguez MA; Rolo D; Grau I; Martín R; Liñares J
Clin Infect Dis; 2009 Jan; 48(1):57-64. PubMed ID: 19035779
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of universal 7-valent pneumococcal conjugate vaccination in Taiwan: a cost-effectiveness analysis.
Wu DB; Rinaldi F; Huang YC; Chang JA; Chang CJ
J Formos Med Assoc; 2013 Mar; 112(3):151-60. PubMed ID: 23473528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
